Document Detail

[Bladder preservation possibilities in the treatment of muscle-invasive bladder cancer].
MedLine Citation:
PMID:  17090976     Owner:  NLM     Status:  MEDLINE    
Radical cystectomy is the standard of treatment for muscle-invasive transitional cell carcinoma of the bladder in European Union and in United States. During the last few decades, several clinical trials were performed with the aim to evaluate new treatment methods as an alternative to radical cystectomy for selected patient groups. According to some clinical trials, it is clear that bladder preservation is possible without compromising overall survival of these patients. Organ preservation requires a combined-modality treatment including transurethral resection of bladder tumor, radiation therapy, and systemic chemotherapy. Incorporation of chemotherapeutic agents such as gemcitabine or taxanes in bladder-sparing protocols improves the results of conservative treatment of locally advanced bladder cancer. Pretreatment selection criteria and the most important prognostic factors are macroscopically complete transurethral resection of bladder tumor, absence of hydronephrosis, and lower T stage.
Jolita Asadauskiene; Eduardas Aleknavicius; Terese Pipiriene Zelviene; Feliksas Jankevicius
Publication Detail:
Type:  English Abstract; Journal Article; Review    
Journal Detail:
Title:  Medicina (Kaunas, Lithuania)     Volume:  42     ISSN:  1648-9144     ISO Abbreviation:  Medicina (Kaunas)     Publication Date:  2006  
Date Detail:
Created Date:  2006-11-08     Completed Date:  2006-12-18     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  9425208     Medline TA:  Medicina (Kaunas)     Country:  Lithuania    
Other Details:
Languages:  lit     Pagination:  781-7     Citation Subset:  IM    
Institute of Oncology, Vilnius University, Vilnius, Lithuania.
Vernacular Title:
Serganciuju invaziniu uroteliniu veziu slapimo pūsle issaugancio gydymo efektyvumas.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antimetabolites, Antineoplastic / administration & dosage,  therapeutic use
Antineoplastic Agents / administration & dosage,  therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carboplatin / administration & dosage,  therapeutic use
Carcinoma, Transitional Cell / drug therapy,  mortality,  pathology,  radiotherapy,  therapy
Cisplatin / administration & dosage,  therapeutic use
Clinical Trials as Topic
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Combined Modality Therapy
Deoxycytidine / administration & dosage,  analogs & derivatives,  therapeutic use
Disease-Free Survival
Dose Fractionation
Doxorubicin / therapeutic use
Methotrexate / therapeutic use
Neoplasm Invasiveness
Neoplasm Staging
Radiation-Sensitizing Agents / administration & dosage,  therapeutic use
Radiotherapy Dosage
Taxoids / administration & dosage,  therapeutic use
Time Factors
Urinary Bladder / pathology
Urinary Bladder Neoplasms / drug therapy,  mortality,  pathology,  radiotherapy,  surgery,  therapy*
Vinblastine / therapeutic use
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 0/Antineoplastic Agents; 0/Radiation-Sensitizing Agents; 0/Taxoids; 15663-27-1/Cisplatin; 23214-92-8/Doxorubicin; 41575-94-4/Carboplatin; 59-05-2/Methotrexate; 865-21-4/Vinblastine; 951-77-9/Deoxycytidine; B76N6SBZ8R/gemcitabine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cognitive function, habitual gait speed, and late-life disability in the National Health and Nutriti...
Next Document:  Exercise as a stressor to the human neuroendocrine system.